GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » HPGC Renmintongtai Pharmaceutical Corp (SHSE:600829) » Definitions » Cyclically Adjusted Revenue per Share

HPGC Renmintongtai Pharmaceutical (SHSE:600829) Cyclically Adjusted Revenue per Share : ¥16.19 (As of Mar. 2024)


View and export this data going back to 1994. Start your Free Trial

What is HPGC Renmintongtai Pharmaceutical Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

HPGC Renmintongtai Pharmaceutical's adjusted revenue per share for the three months ended in Mar. 2024 was ¥4.481. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ¥16.19 for the trailing ten years ended in Mar. 2024.

During the past 12 months, HPGC Renmintongtai Pharmaceutical's average Cyclically Adjusted Revenue Growth Rate was 5.30% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 7.50% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 7.90% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 11.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of HPGC Renmintongtai Pharmaceutical was 20.80% per year. The lowest was 7.10% per year. And the median was 13.70% per year.

As of today (2024-06-08), HPGC Renmintongtai Pharmaceutical's current stock price is ¥5.97. HPGC Renmintongtai Pharmaceutical's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was ¥16.19. HPGC Renmintongtai Pharmaceutical's Cyclically Adjusted PS Ratio of today is 0.37.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of HPGC Renmintongtai Pharmaceutical was 3.69. The lowest was 0.35. And the median was 0.67.


HPGC Renmintongtai Pharmaceutical Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for HPGC Renmintongtai Pharmaceutical's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HPGC Renmintongtai Pharmaceutical Cyclically Adjusted Revenue per Share Chart

HPGC Renmintongtai Pharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.30 13.04 14.03 15.09 16.19

HPGC Renmintongtai Pharmaceutical Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.38 15.60 16.00 16.19 16.19

Competitive Comparison of HPGC Renmintongtai Pharmaceutical's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - Specialty & Generic subindustry, HPGC Renmintongtai Pharmaceutical's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HPGC Renmintongtai Pharmaceutical's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, HPGC Renmintongtai Pharmaceutical's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where HPGC Renmintongtai Pharmaceutical's Cyclically Adjusted PS Ratio falls into.



HPGC Renmintongtai Pharmaceutical Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, HPGC Renmintongtai Pharmaceutical's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=4.481/115.2271*115.2271
=4.481

Current CPI (Mar. 2024) = 115.2271.

HPGC Renmintongtai Pharmaceutical Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 3.736 98.200 4.384
201409 3.671 98.900 4.277
201412 3.805 99.000 4.429
201503 4.665 99.900 5.381
201506 3.647 99.500 4.223
201509 3.391 100.500 3.888
201512 3.662 100.600 4.194
201603 3.975 102.200 4.482
201606 3.814 101.400 4.334
201609 3.596 102.400 4.046
201612 4.144 102.600 4.654
201703 3.583 103.200 4.001
201706 3.321 103.100 3.712
201709 3.855 104.100 4.267
201712 3.054 104.500 3.367
201803 2.943 105.300 3.220
201806 3.018 104.900 3.315
201809 3.258 106.600 3.522
201812 2.949 106.500 3.191
201903 3.390 107.700 3.627
201906 3.400 107.700 3.638
201909 3.863 109.800 4.054
201912 3.752 111.200 3.888
202003 3.233 112.300 3.317
202006 2.808 110.400 2.931
202009 3.790 111.700 3.910
202012 3.942 111.500 4.074
202103 3.728 112.662 3.813
202106 4.314 111.769 4.447
202109 4.435 112.215 4.554
202112 3.587 113.108 3.654
202203 4.013 114.335 4.044
202206 3.927 114.558 3.950
202209 4.573 115.339 4.569
202212 4.114 115.116 4.118
202303 4.576 115.116 4.580
202306 4.520 114.558 4.546
202309 4.398 115.339 4.394
202312 4.423 114.781 4.440
202403 4.481 115.227 4.481

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


HPGC Renmintongtai Pharmaceutical  (SHSE:600829) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

HPGC Renmintongtai Pharmaceutical's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=5.97/16.19
=0.37

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of HPGC Renmintongtai Pharmaceutical was 3.69. The lowest was 0.35. And the median was 0.67.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


HPGC Renmintongtai Pharmaceutical Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of HPGC Renmintongtai Pharmaceutical's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


HPGC Renmintongtai Pharmaceutical (SHSE:600829) Business Description

Traded in Other Exchanges
N/A
Address
No. 76 Hengshan Road, Nangang District, Heilongjiang Province, Harbin, CHN, 150076
HPGC Renmintongtai Pharmaceutical Corp, formerly Harbin Pharm. Group Sanjing Pharmaceutical Shareholding Co Ltd is engaged in the production and sale of pharmaceuticals products in China.
Executives
Yue Xian Zhi senior management
Zhang Li Jun Director

HPGC Renmintongtai Pharmaceutical (SHSE:600829) Headlines

No Headlines